| abstract |
With the present invention, metabolomics biomarkers are used to identify subtypes within the autism spectrum disorder (ASD) population. In one embodiment, levels of the metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) of about six times or greater than the median level in typically developing (TD) individuals or about 2 μM or greater place the individual in an autism subpopulation that includes less than 20% of the total ASD population. Thus, CMPF is a biomarker able to discriminate a subtype of ASD. |